Osteoporosis & bone health

Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis

Osteoporos IntPublished Retrospective cohort study

Authors' conclusion

Romosozumab demonstrated high effectiveness in this real-world cohort, with a substantial proportion achieving high-magnitude BMD responses despite extensive prior treatment. Distinct site-specific predictors emerged: bone turnover and age/Z-score for LS, prior femoral fracture for FN.

Study context

Population
Postmenopausal women with severe osteoporosis who completed 12 months of romosozumab, five Italian centresmean age 69.4 ± 9.9 years
Participants
149 women
Outcome
Romosozumab effectiveness (BMD gain) and predictors of high-magnitude densitometric response (super-responders ≥ 20% BMD gain)
Follow-up
12 months
Methodological detailsmulticentre, real-world, multivariate logistic regression
  • Multicentre
  • Real-world
  • Multivariate logistic regression

Main finding

As reported in the abstract

Mean BMD gain
Mean BMD gain at lumbar spine (LS)
+ 13.7%
Mean BMD gain at femoral neck (FN)
+ 5.9%
Mean BMD gain at total hip (TH)
+ 4.4%
Very good responders (≥ 10%) at LS
65.2%
Very good responders (≥ 10%) at FN
17.8%
Very good responders (≥ 10%) at TH
13.3%
Super-responders (≥ 20%) at LS
17.8%
Super-responders (≥ 20%) at FN
5.9%

Observational data: associations, not effects.

Further findings

Independent predictors of LS super-response

Higher baseline CTX, OR
1.42; p = 0.018
Older age, OR per year
1.10; p = 0.036
Lower baseline LS Z-score, OR
0.29; p = 0.003
  • Multivariate logistic regression

Independent predictor of FN super-response

Prior femoral fracture, OR
14.6; p = 0.020
  • Multivariate logistic regression

Original publication

Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis. Osteoporos Int. Published 14 April 2026. doi:10.1007/s00198-026-07999-3

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.